Details der Publikation - Drug-induced agranulocytosis in the Berlin case

Drug-induced agranulocytosis in the Berlin case–control surveillance study

Purpose Drug-induced agranulocytosis (DIAG) is a rare but serious adverse drug reaction. The Berlin Case–Control Surveillance Study (FAKOS) aimed to identify pharmaceuticals with an increased risk for this condition. Methods Adult patients with acute non-chemotherapy–induced agranulocytosis, developed in hospital or in the outpatient setting, were ascertained by active surveillance in all 51 Berlin hospitals between the years 2000 and 2010. Applying the criteria of the World Health Organization, a standardized drug causality assessment was conducted for each agranulocytosis patient to determine possible drug aetiology. Drug risks were quantified in a case–control design with unconditional logistic regression analysis. Results Sixty-three out of 88 validated cases of agranulocytosis were identified as being at least probably drug-related. Drug causality assessment resulted in 36 pharmaceuticals with a certain or probable relationship to agranulocytosis. Drugs involved in ≥ 3 cases with a probable or certain causality were metamizole (dipyrone) (N = 10), clozapine (N = 6), sulfasalazine (N = 5), thiamazole (N = 5), and carbamazepine (N = 3). In case–control analysis, six drugs were identified with significant odds ratios for DIAG. The highest odds ratios were observed for clozapine, sulfasalazine, and thiamazole. Conclusions Our findings are generally in agreement with those of earlier case–control studies. The spectrum of drugs causing acute agranulocytosis has not changed considerably over recent years, despite many newly marketed drugs. Evidence for induction of agranulocytosis by some new pharmaceuticals is supported..

Medienart:	E-Artikel

Erscheinungsjahr:	2013
Erschienen:	2013

Enthalten in:	Zur Gesamtaufnahme - volume:70
Enthalten in:	European journal of clinical pharmacology - 70(2013), 3 vom: 03. Dez., Seite 339-345

Sprache:	Englisch

Beteiligte Personen:	Huber, Matthias [VerfasserIn] Andersohn, Frank [VerfasserIn] Bronder, Elisabeth [VerfasserIn] Klimpel, Andreas [VerfasserIn] Thomae, Michael [VerfasserIn] Konzen, Christine [VerfasserIn] Meyer, Oliver [VerfasserIn] Salama, Abdulgabar [VerfasserIn] Schrezenmeier, Hubert [VerfasserIn] Hildebrandt, Martin [VerfasserIn] Späth-Schwalbe, Ernst [VerfasserIn] Grüneisen, Andreas [VerfasserIn] Kreutz, Reinhold [VerfasserIn] Garbe, Edeltraut [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Themen:	Agranulocytosis Berlin case–control surveillance study Case–control study Causality assessment Drug-induced

RVK:	RVK Klassifikation ELIB24

Anmerkungen:	© Springer-Verlag Berlin Heidelberg 2013

doi:	10.1007/s00228-013-1618-1

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2090647019

Internformat


LEADER	01000naa a22002652 4500
001	OLC2090647019
003	DE-627
005	20230324002436.0
007	cr uuu---uuuuu
008	230324s2013 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s00228-013-1618-1 \|2 doi
035			\|a (DE-627)OLC2090647019
035			\|a (DE-He213)s00228-013-1618-1-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a PHARM \|q DE-84 \|2 fid
084			\|a ELIB24 \|q VZ \|2 rvk
100	1		\|a Huber, Matthias \|e verfasserin \|4 aut
245	1	0	\|a Drug-induced agranulocytosis in the Berlin case–control surveillance study
264		1	\|c 2013
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Springer-Verlag Berlin Heidelberg 2013
520			\|a Purpose Drug-induced agranulocytosis (DIAG) is a rare but serious adverse drug reaction. The Berlin Case–Control Surveillance Study (FAKOS) aimed to identify pharmaceuticals with an increased risk for this condition. Methods Adult patients with acute non-chemotherapy–induced agranulocytosis, developed in hospital or in the outpatient setting, were ascertained by active surveillance in all 51 Berlin hospitals between the years 2000 and 2010. Applying the criteria of the World Health Organization, a standardized drug causality assessment was conducted for each agranulocytosis patient to determine possible drug aetiology. Drug risks were quantified in a case–control design with unconditional logistic regression analysis. Results Sixty-three out of 88 validated cases of agranulocytosis were identified as being at least probably drug-related. Drug causality assessment resulted in 36 pharmaceuticals with a certain or probable relationship to agranulocytosis. Drugs involved in ≥ 3 cases with a probable or certain causality were metamizole (dipyrone) (N = 10), clozapine (N = 6), sulfasalazine (N = 5), thiamazole (N = 5), and carbamazepine (N = 3). In case–control analysis, six drugs were identified with significant odds ratios for DIAG. The highest odds ratios were observed for clozapine, sulfasalazine, and thiamazole. Conclusions Our findings are generally in agreement with those of earlier case–control studies. The spectrum of drugs causing acute agranulocytosis has not changed considerably over recent years, despite many newly marketed drugs. Evidence for induction of agranulocytosis by some new pharmaceuticals is supported.
650		4	\|a Berlin case–control surveillance study
650		4	\|a Agranulocytosis
650		4	\|a Drug-induced
650		4	\|a Causality assessment
650		4	\|a Case–control study
700	1		\|a Andersohn, Frank \|4 aut
700	1		\|a Bronder, Elisabeth \|4 aut
700	1		\|a Klimpel, Andreas \|4 aut
700	1		\|a Thomae, Michael \|4 aut
700	1		\|a Konzen, Christine \|4 aut
700	1		\|a Meyer, Oliver \|4 aut
700	1		\|a Salama, Abdulgabar \|4 aut
700	1		\|a Schrezenmeier, Hubert \|4 aut
700	1		\|a Hildebrandt, Martin \|4 aut
700	1		\|a Späth-Schwalbe, Ernst \|4 aut
700	1		\|a Grüneisen, Andreas \|4 aut
700	1		\|a Kreutz, Reinhold \|4 aut
700	1		\|a Garbe, Edeltraut \|4 aut
773	0	8	\|i Enthalten in \|t European journal of clinical pharmacology \|d Springer Berlin Heidelberg, 1968 \|g 70(2013), 3 vom: 03. Dez., Seite 339-345 \|h Online-Ressource \|w (DE-627)253722829 \|w (DE-600)1459058-X \|w (DE-576)072372613 \|x 1432-1041 \|7 nnns
773	1	8	\|g volume:70 \|g year:2013 \|g number:3 \|g day:03 \|g month:12 \|g pages:339-345
856	4	0	\|u https://dx.doi.org/10.1007/s00228-013-1618-1 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a FID-PHARM
912			\|a SSG-OPC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_267
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2134
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2433
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	r	v	\|a ELIB24
951			\|a AR
952			\|d 70 \|j 2013 \|e 3 \|b 03 \|c 12 \|h 339-345

Drug-induced agranulocytosis in the Berlin case–control surveillance study

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände